Breathe Well Live Well
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668); Drug: Placebo; Drug: Asthma Reliever Therapies; Drug: Asthma Controller Therapies (Incl. prednisone/prednisolone)
Sponsors: Sanofi; Regeneron Pharmaceuticals
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Drug: MSTT1041A; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting – verified September 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Inadequately Controlled Asthma
Intervention: Biological: Tralokinumab open-label
Sponsor: AstraZeneca
Not yet recruiting – verified September 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Drug: Benralizumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified August 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Drug: CHF 5993 100/6/12.5 µg; Drug: CHF 1535 100/6 µg
Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting – verified February 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Substantial increase in costs for uncontrolled asthma
Medical Xpress The researchers found that asthma was symptomatically controlled, partially controlled, and uncontrolled in 29.4, 39.8, and 30.8 percent of visits, respectively. The average costs for asthma were $134.50 for three months, with 20.5, 47.8, and 31.5 … |
View full post on asthma – Google News
|
Substantial Increase in Costs for Uncontrolled Asthma
Monthly Prescribing Reference (registration) (HealthDay News) — A considerable proportion of patients with mild to moderate asthma are symptomatically uncontrolled, and uncontrolled asthma is associated with significantly increased costs, according to a study published online Nov. 3 in Allergy. |
View full post on asthma – Google News
| Related Articles |
Caregiver treatment satisfaction is improved together with children’s asthma control: Prospective study for budesonide monotherapy in school-aged children with uncontrolled asthma symptoms.
Allergol Int. 2015 Oct;64(4):371-6
Authors: Yoshihara S, Kanno N, Fukuda H, Arisaka O, Arita M, Sekine K, Yamaguchi K, Tsuchida A, Yamada Y, Watanabe T, Shimizu T, Nishikawa K, Nishimuta T
Abstract
BACKGROUND: If asthmatic children cannot obtain sufficient control of their disease, not only do they suffer from asthma symptoms, but the daily life activities of their caregivers are also disrupted. We investigated the effectiveness of an inhaled corticosteroid (ICS) for symptom control in previously ICS-untreated school-aged asthmatic children as well as caregiver treatment satisfaction (CTS).
METHODS: A multicenter, open-label, single-arm study on 12-week ICS (budesonide Turbuhaler(®)) monotherapy was undertaken in subjects aged 5-15 years with bronchial asthma not treated with ICS during the previous 3 months. At 0, 4, 8, and 12 weeks after start of ICS administration, Japanese Pediatric Asthma Control Program (JPAC) scores, and CTS scores were summated and lung function measured. At weeks 0 and 12, questionnaires on caregiver anxiety were also assessed.
RESULTS: Seventy-five patients were enrolled, and 69 assessed. Ninety percent of subjects had been treated with asthma controller medication except ICS before study enrollment. JPAC score and CTS score were improved significantly at weeks 4, 8, and 12 (p < 0.001). With regard to CTS, more than half of caregivers showed a perfect score at weeks 8 and 12. There was a significant correlation between JPAC score and CTS score. Lung function and caregiver anxiety were also improved, and good compliance with treatment was observed during the intervention.
CONCLUSIONS: If treating ICS-untreated school-aged asthmatic children with uncontrolled symptoms, ICS monotherapy can improve CTS along with improving asthma control.
PMID: 26433534 [PubMed – in process]
View full post on pubmed: asthma
|
Emergency rooms test new ways to help minority children with uncontrolled …
Medical Xpress The rates of asthma in children are unusually high in Chicago and the respiratory disorder disproportionately affects African-American children. To address the issue, Rush University Medical Center and six other major medical centers in Chicago are … |
View full post on asthma – Google News
Monthly Prescribing Reference (registration) |
LAMA LABA Uncontrolled Asthma ICS
Monthly Prescribing Reference (registration) Long-acting muscarinic antagonists (LAMA) have been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and are now being considered for patients with uncontrolled asthma as add-on treatment. A review in the Cochrane … |
View full post on asthma – Google News